Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica Ailani

Showing results (81-90 of 114) with videos related to

Pageof 12
Sort By:
Clinical Drug Investigation|March 7, 2022
Correction to: Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)Stewart J Tepper, Jessica Ailani, Janet H Ford, et al.
Headache|November 12, 2020
Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM StudyRichard B Lipton, Joshua M Cohen, Kristen Bibeau, et al.
Pain and Therapy|April 17, 2026
Long-Term Reductions in Headache Frequency, Severity, and Disability with Eptinezumab in Adults with Chronic Migraine: Results from the PREVAIL TrialAmaal J Starling, David Kudrow, Neha Kapur, et al.
Cephalalgia : an International Journal of Headache|November 19, 2024
Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene-related peptide monoclonal antibodiesJessica Ailani, Anjana Lalla, Rashmi B Halker Singh, et al.
Cephalalgia : an International Journal of Headache|April 7, 2026
Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label studyJohn Rothrock, Umer Najib, Jessica Ailani, et al.
Headache|January 9, 2020
Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension TrialJessica Ailani, Richard B Lipton, Susan Hutchinson, et al.
Cephalalgia : an International Journal of Headache|July 29, 2020
Non-invasive vagus nerve stimulation for primary headache: A clinical updateStephen D Silberstein, Hsiangkuo Yuan, Umer Najib, et al.
Headache|January 31, 2026
Towards a standardized process of onboarding advanced practice providers into headache medicine practices in the United States: Expert consensus from the American Headache Society practice management committeeCalli Cook, Marshall C Freeman, Jessica Ailani, et al.
Headache|September 9, 2024
Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraineJessica Ailani, Pranav Gandhi, Anjana Lalla, et al.
Headache|January 7, 2026
Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME (US) studyJessica Ailani, Rose Okonkwo, Elizabeth Johnston, et al.
Pageof 12

Showing results (81-90 of 114) with videos related to

Sort By:
Pageof 12
Clinical Drug Investigation|March 7, 2022
Correction to: Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)Stewart J Tepper, Jessica Ailani, Janet H Ford, et al.
Headache|November 12, 2020
Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM StudyRichard B Lipton, Joshua M Cohen, Kristen Bibeau, et al.
Pain and Therapy|April 17, 2026
Long-Term Reductions in Headache Frequency, Severity, and Disability with Eptinezumab in Adults with Chronic Migraine: Results from the PREVAIL TrialAmaal J Starling, David Kudrow, Neha Kapur, et al.
Cephalalgia : an International Journal of Headache|November 19, 2024
Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene-related peptide monoclonal antibodiesJessica Ailani, Anjana Lalla, Rashmi B Halker Singh, et al.
Cephalalgia : an International Journal of Headache|April 7, 2026
Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label studyJohn Rothrock, Umer Najib, Jessica Ailani, et al.
Headache|January 9, 2020
Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension TrialJessica Ailani, Richard B Lipton, Susan Hutchinson, et al.
Cephalalgia : an International Journal of Headache|July 29, 2020
Non-invasive vagus nerve stimulation for primary headache: A clinical updateStephen D Silberstein, Hsiangkuo Yuan, Umer Najib, et al.
Headache|January 31, 2026
Towards a standardized process of onboarding advanced practice providers into headache medicine practices in the United States: Expert consensus from the American Headache Society practice management committeeCalli Cook, Marshall C Freeman, Jessica Ailani, et al.
Headache|September 9, 2024
Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraineJessica Ailani, Pranav Gandhi, Anjana Lalla, et al.
Headache|January 7, 2026
Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME (US) studyJessica Ailani, Rose Okonkwo, Elizabeth Johnston, et al.
Pageof 12